X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES AJANTA PHARMA JUBILANT LIFE SCIENCES/
AJANTA PHARMA
 
P/E (TTM) x 17.1 20.4 83.7% View Chart
P/BV x 4.5 4.8 93.7% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
AJANTA PHARMA
Mar-18
JUBILANT LIFE SCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1871,818 10.3%   
Low Rs651,106 5.9%   
Sales per share (Unadj.) Rs364.3239.5 152.1%  
Earnings per share (Unadj.) Rs6.852.8 13.0%  
Cash flow per share (Unadj.) Rs24.559.5 41.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %2.40-  
Book value per share (Unadj.) Rs164.9230.0 71.7%  
Shares outstanding (eoy) m159.2888.77 179.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.1 5.7%   
Avg P/E ratio x18.427.7 66.4%  
P/CF ratio (eoy) x5.124.6 20.9%  
Price / Book Value ratio x0.86.4 12.0%  
Dividend payout %43.80-   
Avg Mkt Cap Rs m20,061129,782 15.5%   
No. of employees `0006.26.8 91.0%   
Total wages/salary Rs m11,0523,765 293.6%   
Avg. sales/employee Rs Th9,383.03,128.4 299.9%   
Avg. wages/employee Rs Th1,786.9554.0 322.5%   
Avg. net profit/employee Rs Th176.3689.7 25.6%   
INCOME DATA
Net Sales Rs m58,03421,258 273.0%  
Other income Rs m191242 78.9%   
Total revenues Rs m58,22421,499 270.8%   
Gross profit Rs m5,7866,584 87.9%  
Depreciation Rs m2,812596 471.8%   
Interest Rs m3,2374 78,956.1%   
Profit before tax Rs m-726,226 -1.2%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,539 45.2%   
Profit after tax Rs m1,0904,686 23.3%  
Gross profit margin %10.031.0 32.2%  
Effective tax rate %-965.924.7 -3,906.9%   
Net profit margin %1.922.0 8.5%  
BALANCE SHEET DATA
Current assets Rs m29,28012,236 239.3%   
Current liabilities Rs m38,9123,461 1,124.5%   
Net working cap to sales %-16.641.3 -40.2%  
Current ratio x0.83.5 21.3%  
Inventory Days Days8460 140.1%  
Debtors Days Days5184 60.0%  
Net fixed assets Rs m55,71211,140 500.1%   
Share capital Rs m155177 87.3%   
"Free" reserves Rs m20,96820,237 103.6%   
Net worth Rs m26,26520,414 128.7%   
Long term debt Rs m17,16910 169,988.1%   
Total assets Rs m88,60624,486 361.9%  
Interest coverage x1.01,519.4 0.1%   
Debt to equity ratio x0.70 132,117.8%  
Sales to assets ratio x0.70.9 75.4%   
Return on assets %4.919.2 25.5%  
Return on equity %4.223.0 18.1%  
Return on capital %11.630.5 37.9%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00411,667 188.6%   
Fx outflow Rs m11,7491,616 727.3%   
Net fx Rs m10,25510,052 102.0%   
CASH FLOW
From Operations Rs m8,0262,854 281.2%  
From Investments Rs m-1,744-2,604 67.0%  
From Financial Activity Rs m-4,447-2 222,370.0%  
Net Cashflow Rs m1,834248 739.4%  

Share Holding

Indian Promoters % 45.6 73.8 61.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 1.6 561.3%  
FIIs % 21.2 7.6 278.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 17.0 124.1%  
Shareholders   23,815 20,968 113.6%  
Pledged promoter(s) holding % 15.9 4.4 361.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 21, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - DR. REDDYS LAB COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS